Isis shares buoyed by new cholesterol data

Shares of Isis surged this morning on its updated Phase II trial data of ISIS 301012 in patients with homozygous familial hypercholesterolemia. Three patients with a rare genetic condition that resulted in extremely high cholesterol levels received elevated doses of the drug and saw their cholesterol levels cut in half. The three HoFH patients dosed with 300 mg/week of ISIS 301012 for twelve weeks have now completed treatment. With ISIS 301012, the patients achieved 45%, 50% and 51% additional reductions in LDL-cholesterol beyond that achieved with maximally-tolerated lipid-lowering therapy, with similar reductions in apoB of 45%, 43% and 54%.

- here's the AP report on Isis
- and here's the release

Related story
Mid-stage cholesterol data sends Isis stock soaring Report

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.